Cite
HARVARD Citation
Hurvitz, S. et al. (n.d.). 370TiPA phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer. Annals of oncology. p. . [Online].